{"id":558728,"date":"2026-07-15T12:30:00","date_gmt":"2026-07-15T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=558728"},"modified":"2026-07-15T13:19:12","modified_gmt":"2026-07-15T11:19:12","slug":"sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali\/","title":{"rendered":"SGLT-2-i e GLP-1-RA: miglioramento significativo degli esiti renali"},"content":{"rendered":"\n

Circa il 30\u201340% dei pazienti affetti da diabete di tipo 2 sviluppa nel corso della malattia una malattia renale cronica (CKD). In studi \u00ablandmark\u00bb quali CREDENCE, DAPA-CKD, EMPA-KIDNEY e in alcuni altri, gli inibitori dell\u2019SGLT-2 (sodium-glucose linked transporter 2)<\/em>hanno ottenuto benefici dimostrabili sugli endpoint renali; inoltre, lo studio FLOW ha ormai dimostrato che anche il GLP-1 (Glucagon-like peptide-1)-RA<\/em>. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Circa il 30\u201340% dei pazienti affetti da diabete di tipo 2 sviluppa nel corso della malattia una malattia renale cronica (CKD). In studi \u00ablandmark\u00bb quali CREDENCE, DAPA-CKD, EMPA-KIDNEY e in……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":558732,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Malattia renale cronica nei pazienti affetti da diabete di tipo 2: terapia ottimizzata basata sull\u2019evidenza","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11550,11392,11519,11306,11420,11515],"tags":[24240,12955,94729,66553,23402,12013,94734,44151,20730,65619,94731,12969,94732,18622,94733],"powerkit_post_featured":[],"class_list":["post-558728","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-it","category-endocrinologia-e-diabetologia","category-formazione-continua","category-medicina-interna-generale","category-nefrologia-it","category-studi","tag-canagliflozin-it","tag-ckd-it","tag-credence","tag-dapa-ckd-it","tag-dapagliflozin-it","tag-diabete-di-tipo-2-it","tag-effetti-nefroprotettivi","tag-empagliflozin-it","tag-forxiga-it","tag-glp-1-ra-it-2","tag-jardiance","tag-malattia-renale-cronica","tag-ozempic","tag-sglt-2-i-it","tag-studio-flow","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-31 00:36:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":558765,"slug":"sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais","post_title":"SGLT-2-i e GLP-1-RA: melhoria significativa nos par\u00e2metros renais","href":"https:\/\/medizinonline.com\/pt-pt\/sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais\/"},"es_ES":{"locale":"es_ES","id":558772,"slug":"inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales","post_title":"Inhibidores de SGLT-2 y agonistas selectivos del GLP-1: mejora significativa de los criterios de valoraci\u00f3n renales","href":"https:\/\/medizinonline.com\/es\/inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/558728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=558728"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/558728\/revisions"}],"predecessor-version":[{"id":558733,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/558728\/revisions\/558733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/558732"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=558728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=558728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=558728"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=558728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}